<DOC>
	<DOCNO>NCT01046669</DOCNO>
	<brief_summary>To compare safety efficacy PMX cartridge base mortality 28-days subject septic shock high level endotoxin treat standard medical care plus use PMX cartridge , versus subject receive standard medical care alone .</brief_summary>
	<brief_title>Safety Efficacy Polymyxin B Hemoperfusion ( PMX ) Septic Shock</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Endotoxemia</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<criteria>Hypotension require vasopressor support The subject must receive intravenous fluid resuscitation Documented suspect infection Endotoxin Activity Assay ≥ 0.60 EAA unit Evidence least 1 new onset organ dysfunction Inability achieve maintain minimum mean arterial pressure ( MAP ) 65mmHg Subject end stage renal disease require chronic dialysis There clinical support nonseptic shock Subject chest compression part CPR Subject acute myocardial infarction ( AMI ) Subject uncontrolled hemorrhage Major trauma within 36 hour screen Subject severe granulocytopenia HIV infection last know suspect CD4 count &lt; 50/mm3 Subject sustain extensive thirddegree burn Body weight &lt; 35 kg ( 77 pound ) Known hypersensitivity polymyxin B Subject know sensitivity allergy heparin Subject screen MOD score ≤9</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>